Angiotech's obligation to accept for payment and to pay for Notes validly tendered and not withdrawn pursuant to the tender offer is conditioned upon (a) the Minimum Tender Condition, (b) the consummation of the concurrently announced investment in API which requires approval from Angiotech's shareholders and (c) satisfaction of certain general conditions.
Cautionary Statement Regarding Forward-Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the second half of 2008 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development and our plans and anticipated effects of the transaction described in this press release. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.
Many such risks, uncertainties and other factors are taken into account
as part of our assumptions underlying these forward-looking statements and
include, among others, the fol
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved